BEIGF — BeOne Medicines Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1651308 ·
Switzerland
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,705,071,000 | 1,530,541,000 | 325,047,000 | 237,007,000 | 9,175,615,000 | 5,098,041,000 | 4,001,617,000 |
| Mar 2026 | 1,513,438,000 | 1,346,223,000 | 249,902,000 | 227,357,000 | 8,553,619,000 | 4,791,676,000 | 3,793,177,000 |
| Dec 2025 | 1,498,170,000 | 1,355,748,000 | 185,035,000 | 66,502,000 | 8,188,573,000 | 4,547,530,000 | 3,827,379,000 |
| Sep 2025 | 1,412,284,000 | 1,215,774,000 | 163,114,000 | 124,841,000 | 7,632,586,000 | 4,036,868,000 | 3,503,260,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,484,056,000
Investing CF
$-182,472,000
Financing CF
$1,120,781,000
CapEx
$-175,080,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.41
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-7,855,539,000
Inventory
$732,603,000
Receivables
$1,070,955,000
ST Investments
—
EBIT TTM
$1,020,401,000
Pretax Income TTM
$868,079,000
Interest Exp TTM
$87,623,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,128,963,072
EBITDA
$1,071,609,024
Free Cash Flow
$879,021,888
Enterprise Value
$29,390,401,536
Total Cash
$5,098,040,832
Total Debt
$2,049,524,992
Shares Out
1,355,532,838
Trailing EPS
$0.43
Book Value
$3.52
ROE
14.7%
ROA
7.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,343,033,000 | 447,136,000 | 286,933,000 | 8,188,573,000 | 3,827,379,000 | 4,361,194,000 | 1,127,580,000 |
| Dec 2024 | 3,810,241,000 | -568,199,000 | -644,786,000 | 5,920,910,000 | 2,588,688,000 | 3,332,222,000 | -140,631,000 |
| Dec 2023 | 2,458,779,000 | -1,207,736,000 | -881,708,000 | 5,805,275,000 | 2,267,948,000 | 3,537,327,000 | -1,157,453,000 |
| Dec 2022 | 1,415,921,000 | -1,789,665,000 | -2,003,815,000 | 6,379,290,000 | 1,995,935,000 | 4,383,355,000 | -1,496,619,000 |
TTM Snapshot
Revenues TTM
$2,304,542,000
NetIncome TTM
$-900,662,000
OpCashFlow TTM
$0
Assets (Latest)
$5,920,910,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
2026-09-05 23:06 · Yahoo
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
2026-09-05 03:09 · Yahoo
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
2026-09-04 18:44 · Yahoo
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
2026-09-01 17:01 · Yahoo
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
2026-09-01 16:35 · Yahoo
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
2026-09-01 10:00 · Yahoo
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
2026-08-31 19:00 · Yahoo
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
2026-08-31 10:00 · Yahoo
Generative "AI" Macro Data Shows U.S. Impacts
2026-08-27 20:54 · Yahoo
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
2026-08-27 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.